In sustained rare disease push, Recordati lays out $825M upfront …
WEB2 days ago — Enjaymo reeled in sales of around 100 million euros ($110 million) over 12 months ending in August, Recordati said in its release. The drug is expected to generate revenues in the vicinity of 150 ...
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For …
WEB2 days ago — Enjaymo generated approximately 100 million euros ($109.70 million) in revenue over the last 12 months as of August 2024 and is expected to generate revenue of over 150 million euros in fiscal ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB2 days ago — Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB2 days ago — Global News Select Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million Provided by ... Enjaymo's revenue amounted to around 100 million euros ($110.3 million) for the 12 months to ...
WEBNEWS RELEASE Registered office VIA M. CIVITALI, 1 20148 MILAN, ITALY TEL. +39 0248787.1 MILAN ECONOMIC AND ADMINISTRATIVE INDEX (REA) 401832 FAX +39 0240073747 ... Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD. In 2022, it was granted approval by the U.S. Food and Drug ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB3 days ago — Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
Sanofi’s rare disease drug finds yet another home
WEB3 days ago — By 2017, it had been snapped up by Biogen’s hemophilia-focused spin off Bioverativ. John Cox, the then-CEO of Bioverativ, said at the time that Enjaymo was a central asset in the deal and filled an important gap in the company’s research efforts. Enjaymo, however, would move to yet another owner in 2018, when Sanofi bought Bioverativ for ...
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential …
WEB2 days ago — Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
WEB3 days ago — Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. The terms of the acquisition include an upfront payment of $825m from Recordati to Sanofi, plus additional milestone payments ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEB2 days ago — Recordati said it had signed an agreement for the rights to Enjaymo, a biologic which is the only targeted product for the treatment of CAD approved by the U.S. Food and Drug Administration (FDA).
- Some results have been removed